DICERNA PHARMACEUTICALS, INC. Inactive Instrument
Dicerna Pharmaceuticals, Inc.
Equities
DRNA
US2530311081
Biotechnology & Medical Research
Presenter SpeechNavin Jacob (Analysts)Good morning. Welcome to the UBS Global Healthcare Confe...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The Company's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
| 1st Jan change | Capi. | |
|---|---|---|
| +8.29% | 114B | |
| +10.21% | 104B | |
| -11.90% | 22.41B | |
| +0.38% | 22.28B | |
| -5.57% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
